Louise Bannon: Thomas Reiser to Step Down as ISTH Executive Director
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, reposted from International Society on Thrombosis and Haemostasis on LinkedIn:
”Today, the International Society on Thrombosis and Haemostasis (ISTH) shared that Thomas Reiser will step down as Executive Director at the end of 2025.
Tom has led the Society with dedication and strategic vision for more than 14 years, and we are deeply grateful for his tremendous service, mentorship and commitment to strengthening our global community. We look forward to continuing to work closely with him through the remainder of the year as we prepare for this transition.
I am honored to step into the role of Interim Executive Director on January 1 and it is a privilege to serve our members, partners and the global thrombosis and hemostasis community during this important chapter for the Society.
Our mission remains clear and our momentum strong. In the months ahead, I look forward to partnering with our exceptional staff, volunteer leaders and valued stakeholders to continue advancing science, education and advocacy for the benefit of patients worldwide.
To all who support our work, especially our talented staff, thank you. Your dedication and heart power everything we do. I feel fortunate to work alongside you and look forward to continuing our important work together in the months ahead.”
Quoting International Society on Thrombosis and Haemostasis‘s post:
”The ISTH announces that Thomas Reiser will step down from his position as Executive Director, following a commendable 14-year period of leadership at the Society. As part of a carefully planned transition, the ISTH Council appoints Louise St. Germain, ISTH Director of Membership, Marketing and External Relations, to the role of Interim Executive Director effective on January 1, 2026. As the search for a permanent Executive Director commences, the ISTH looks forward to the opportunities ahead and to the Society continuing to evolve, innovate and strengthen its impact for the benefit of the global thrombosis and hemostasis community.
Read more.”
Stay updated with Hemostasis Today.
-
Jun 3, 2026, 17:18Giacomo Rossi: Cysteine and Gut Health – MIT Finds the Switch
-
Jun 3, 2026, 17:00Amin Ullah: Presence of RBCs of Unequal Sizes in a Peripheral Blood Smear – Anisocytosis of RBC
-
Jun 3, 2026, 16:59Jean Connors: Discussing Cancer-Associated Thrombosis at the Japanese Society of Thrombosis and Hemostasis
-
Jun 3, 2026, 16:54Ayush Bhowmik: Failed Drug Became the World’s Most Widely Used Blood Thinner
-
Jun 3, 2026, 16:13Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
-
Jun 3, 2026, 16:08Pedro Henrique Las Casas: How Anticoagulant Agents and Quercetin Influence Cancer Cell Procoagulant Activity
-
Jun 3, 2026, 16:07Suraj Wilson: Back From ASCO 2026 With A Renewed Commitment To Cancer Research
-
Jun 3, 2026, 16:06Kerin A. Da Cruz: MSTU Team Is Creating The Future of Stroke Care In the Northeast Florida
-
Jun 3, 2026, 16:06Andrew Lee: Examining Rare Clotting Disorders After Adenovirus-Based COVID-19 Vaccination